Literature DB >> 11162688

In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis.

A Tauer1, T Knerr, T Niwa, T P Schaub, C Lage, J Passlick-Deetjen, M Pischetsrieder.   

Abstract

Conventional peritoneal dialysis fluids (PDFs) lead to formation of advanced glycation end-products (AGE) in the peritoneal membrane. In this study, we investigated in vitro the dependence of AGE formation on regular changes of PDFs, as performed during continuous ambulatory peritoneal dialysis (CAPD), and on the contribution of high glucose concentration versus glucose degradation products (GDPs). Under conditions similar to CAPD, protein glycating activity of a conventional single chamber bag PDF (CAPD 4.25%), two double chamber bag PDFs (CAPD Balance 4.25% and CAPD Bicarbonate 4.25%) and a sterile filtered control was measured in vitro by N(epsilon)-(carboxymethyl)lysine (CML) and imidazolones, two well characterized, physiologically relevant AGE structures. Regular changes of PDFs increased AGE formation (CML 3.3-fold and imidazolone 2.6-fold) compared to incubation without changes. AGE formation by CAPD 4.25% was increased compared to control (imidazolones 7.9-fold and CML 3.3-fold) and the use of double chamber bag PDFs led to a decrease of imidazolones by 79% (CAPD Bicarbonate 4.25%) and by 66% (CAPD Balance 4.25%) and to CML contents similar to the control. These results indicate that a major part of AGEs were formed by GDPs in PDFs, whereas only a minor part was due to high glucose concentration. The use of double chamber bag fluids can reduce AGE formation considerably.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162688     DOI: 10.1006/bbrc.2001.4294

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 2.  Peritoneal damage by peritoneal dialysis solutions.

Authors:  Takafumi Ito; Noriaki Yorioka
Journal:  Clin Exp Nephrol       Date:  2008-02-15       Impact factor: 2.801

3.  A new neutral-pH low-GDP peritoneal dialysis fluid.

Authors:  Rainer Himmele; Lynn Jensen; Dominik Fenn; Chih-Hu Ho; Dixie-Ann Sawin; Jose A Diaz-Buxo
Journal:  Perit Dial Int       Date:  2012-03-01       Impact factor: 1.756

4.  Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.

Authors:  Nobuhiro Ayuzawa; Yoshitaka Ishibashi; Yutaka Takazawa; Haruki Kume; Toshiro Fujita
Journal:  Perit Dial Int       Date:  2011-07-31       Impact factor: 1.756

5.  Unchanged serum levels of advanced glycation endproducts in patients with liver disease.

Authors:  Moritz Butscheid; Christian Schäfer; Stefanie Brenner; Dominik Alscher; Thomas Mürdter; Toshimitsu Niwa; Matthias Frischmann; Monika Pischetsrieder; Ulrich Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-15       Impact factor: 3.195

6.  Degradation and de novo formation of nine major glucose degradation products during storage of peritoneal dialysis fluids.

Authors:  Sabrina Gensberger-Reigl; Ingrid Weigel; Joachim Stützer; Andrea Auditore; Tim Nikolaus; Monika Pischetsrieder
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.